Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial.
Topline interim data analysis from a Phase 3 ENSEMBLE clinical trial for an investigational single-dose #COVID19 vaccine candidate announced: http://bit.ly/3ck3LwX
Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination
85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28
Protection Against Severe Disease Across Geographies, Ages, and Multiple Virus Variants, including the SARS-CoV-2 Variant from the B.1.351 Lineage [1] Observed in South Africa
Single-shot compatible with standard vaccine distribution channels provides a vital tool in a pandemic setting
The B.1.351 lineage also known as 501Y.V2 variant and 20H/501Y.V2 (formerly 20C/501Y.V2) is a variant of SARS-CoV-2, the virus that causes COVID-19
As the battle against #COVID19 continues, so does "The Road to a Vaccine." Join host Lisa Ling as she speaks with experts from around the globe to understand the latest developments from the scientific community. Watch LIVE Tuesday, February 2 at 12 PM ET: http://bit.ly/2YTWgpB
